CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
We received an updated WNV package insert; please note the manufacturer and license number has been ...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization